Skip to content

Study on the Effectiveness and Safety of Temporal Interference Stimulation in Treating Patients with Severe Consciousness Disorders

Study on the Effectiveness and Safety of Temporal Interference Stimulation in Treating Patients with Severe Consciousness Disorders

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100667
Enrollment
Unknown
Registered
2025-04-14
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorders of Consciousness

Interventions

Temporal Interference Stimulation group:Temporal Interference Stimulation
Sham Temporal Interference Stimulation group:Sham Temporal Interference Stimulation

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Severe consciousness disorder patients aged 18 to 65 years old, regardless of gender; 2. Patients with severe consciousness disorders, namely a minimally conscious state or vegetative state that lasts for 28 days or more; 3. Patients with normal body temperature, stable vital signs, spontaneous breathing, tracheotomy without the use of a metal cannula and with a small amount of sputum, and who are eligible for magnetic resonance imaging (MRI) examination; 4. Written informed consent obtained from the patient's family members in advance.

Exclusion criteria

Exclusion criteria: 1. Individuals with a previous history of significant neuropsychiatric and other major disorders such as those involving the heart, lung, liver, and kidney; 2. Those who have undergone V-P shunt or Ommaya reservoir implantation and other procedures that may influence the analysis of magnetic resonance scanning signals; 3. Patients who are scheduled for V-P shunt or Ommaya reservoir implantation in the near future; 4. Pregnant women; 5. Those who have participated in other drug or device clinical trials; 6. Patients with poorly controlled epilepsy in the recent period; 7. Those with infections at the TI stimulation site or compromised skin integrity at the electrode placement site; 8. Those currently taking medications prone to inducing epilepsy, such as quinolone drugs; 9. Those with intracranial infections, intracranial tumors, or metallic objects within the cranium; 10. Those allergic to electrode gel or adhesives; 11. Those with implanted electronic devices within the body; 12. Those with severe cardiac disorders and those equipped with cardiac pacemakers.

Design outcomes

Primary

MeasureTime frame
Effective rate of awakening;

Secondary

MeasureTime frame
Behavioral improvement;Behavioral improvement;Behavioral improvement;Behavioral improvement;Behavioral improvement;Security indicators;

Countries

China

Contacts

Public ContactXuehai Wu

Huashan Hospital, Fudan University

wuxuehai2013@163.com+86 21 52887732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026